在 COVID-19 大流行期间诊断羟氯喹肌病面临的挑战。

Challenges in diagnosing hydroxychloroquine myopathy during the COVID-19 pandemic.

机构信息

Department of Neuropathology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.

Discipline of Pathology, School of Medical Sciences, Brain and Mind Centre, The University of Sydney, Sydney, New South Wales, Australia.

出版信息

Intern Med J. 2020 Dec;50(12):1559-1562. doi: 10.1111/imj.15092.

DOI:10.1111/imj.15092

PMID:33354884

Abstract

Hydroxychloroquine is being used for COVID-19 symptoms and in clinical trials, but can cause a toxic myopathy that leads to muscle weakness. A review of skeletal muscle biopsies from patients with hydroxychloroquine myopathy gives pointers of steps that can be taken to diagnose this toxic myopathy early and help differentiate it from COVID-19-related muscle weakness.

摘要

羟氯喹被用于治疗 COVID-19 症状和临床试验，但可引起导致肌肉无力的毒性肌病。对羟氯喹肌病患者的骨骼肌活检进行综述，可提供有助于早期诊断这种毒性肌病并帮助其与 COVID-19 相关肌肉无力相鉴别的步骤。